Last reviewed · How we verify
OCU400
At a glance
| Generic name | OCU400 |
|---|---|
| Sponsor | Ocugen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa (PHASE3)
- Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis (PHASE1, PHASE2)
- Expanded Access Program for RP in Adults
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OCU400 CI brief — competitive landscape report
- OCU400 updates RSS · CI watch RSS
- Ocugen portfolio CI